Caplyta From Intra-Cellular Therapies, Inc
July 6th 2020Caplyta is an atypical antipsychotic and is thought to exert its effect through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors.
New Regulations Aim to Reform Self-Referral Stark Law
July 2nd 2020When the Stark Law, or ethics in patient referrals act, was passed in 1989, its purpose was to prevent physicians from referring patients to designated health service entities in which they had financial interest.
Toxicity Is a Risk of PAMORA Interactions
Peripherally acting M-opioid receptor antagonists can improve quality of life but differ variably by impact from concomitant medications.
Stay Up to Date on New COVID-19 Data in Specific Populations
June 15th 2020As the overall data on this illness continue to emerge, it will be important for health care providers to watch its impact on different populations and to serve as a source of reliable information for them.